key: cord-0781243-tzikloje
authors: Liu, Xi; Wen, Yan-Zi; Huang, Zi-Liang; Shen, Xia; Wang, Jun-Hao; Luo, Yi-Hai; Chen, Wen-Xin; Lun, Zhao-Rong; Li, Hui-Bin; Qu, Liang-Hu; Shan, Hong; Zheng, Ling-Ling
title: SARS-CoV-2 Causes a Significant Stress Response Mediated by Small RNAs in the Blood of COVID-19 Patients
date: 2021-12-31
journal: Mol Ther Nucleic Acids
DOI: 10.1016/j.omtn.2021.12.034
sha: 3fa538d5b7a54ba9e0b03a41d60a45b1d0de7d56
doc_id: 781243
cord_uid: tzikloje

SARS-CoV-2 has had a serious impact on the world. In this study, small RNAs from the blood of COVID-19 patients with moderate or severe symptoms were extracted for high-throughput sequencing and analysis. Interestingly, the levels of a special group of tRNA-derived small RNAs (tsRNAs) were found to be dramatically upregulated after SARS-CoV-2 infection, particularly in COVID-19 patients with severe symptoms. In particular, the 3'CCA tsRNAs from Gly-tRNA were highly consistent with the inflammation indicator C-reactive protein (CRP). In addition, we found that the majority of significantly changed microRNAs (miRNAs) were associated with endoplasmic reticulum (ER)/unfolded protein response (UPR) sensors, which may lead to the induction of proinflammatory cytokine and immune responses. This study found that SARS-CoV-2 infection caused significant changes in the levels of stress-associated small RNAs in patient blood and their potential functions. Our research revealed that the cells of COVID-19 patients undergo tremendous stress and respond, which can be reflected or regulated by sncRNAs, thus providing potential thought for therapeutic intervention in COVID-19 by modulating small RNA levels or activities.

3) ( Figure 2D&E ). 121 tsRNAs can be divided into 5 types according to their different sources, tRF-5 (5' tRF), tRF-3 122 (3' CCA tRF), tRF-1 (3' trailer tRF), tRF-i (internal tRF) and tRH (tRNA half), each of which 123 has a related function. [24] [25] [26] To investigate whether the upregulated tsRNAs in COVID- 19 124 patients are type specific, the source and length distribution of tsRNAs were further analysed. 125

To our surprise, the majority of 22 nt tsRNAs were derived from tRF-3 (3'CCA tRF), and their 126 expression increased by approximately 20% in severe cases ( Figure 2F-H) . 127

In particular, the expression level of tsRNAs derived from the 3'CCA region of tRNA-Gly 128 ( Figure 3A&B ) gradually increased with the development of the disease ( Figure 3C ). Compared 129 with those in healthy controls, their levels were upregulated more than 4-fold in severe patients 130 according to the sequencing data ( Figure 3C ) and more than 200-fold according to qRT-PCR 131 results ( Figure 3D ). More interestingly, we analysed 30 clinical characteristics of patients (Table  132 S1) and finally found that, in patients with a high level of the inflammation marker C-reactive 133 protein (CRP), this tsRNA was significantly upregulated (logFC = 1. 28 Figure 4A ). For COVID-19 patients, moderate and severe cases could be basically grouped 141 into two categories, indicating that the expression level of miRNAs in the blood was 142 significantly different between COVID-19 patients and healthy controls, which was consistent 143 with the clinical classification of patients. To illustrate that the expression level of these 144 miRNAs is mainly driven by the disease rather than gender, treatment methods or other factors, 145 J o u r n a l P r e -p r o o f we conducted the different regression modeling ( Figure S1 ). Across the miRNAs tested, we 146 observed no association between the miRNA expressions and sex and some slight γ globulin 147 treatment effects on the miRNA expressions ( Figure S1A ). Nevertheless, in a joint regression 148 including these factors as covariates in the patients, the γ globulin treatment effects on the 149 miRNA expressions can all be captured by the disease status. Namely, the variation in the 150 miRNA expressions is mainly driven by the disease status. 151

Furthermore, these miRNAs were divided into high expression groups and low expression 152 groups according to their average expression levels compared with the middle of these miRNAs 153 expression range ( Figure 4B ). Interestingly, six highly expressed miRNAs were all 154 downregulated in severe patients. We therefore named these miRNAs HI-DOWN miRNAs 155 (highly expressed and significantly downregulated in severe patients). 156

Target molecules of differentially expressed miRNAs are enriched in the endoplasmic 157 reticulum stress pathway 158

Based on miRNA function, we investigated 6053 experimentally validated target genes of the 159 differentially expressed miRNAs and built interaction networks among them. Furthermore, GO 160 enrichment and KEGG pathway analysis revealed that these genes were significantly enriched 161 in the endoplasmic reticulum (ER) lumen ( Figure 5A ) and involved in the "protein digestion 162 and absorption" and "protein processing in endoplasmic reticulum" pathways ( Figure 5B ). 163

Studies have found that coronavirus proteins can cause damage to the endoplasmic reticulum 164 and affect the secretory pathway. 27, 28 In addition, the endoplasmic reticulum has been suggested 165 as a potential therapeutic target for COVID-19 management. 29, 30 We therefore speculated 166 whether the activation of ER-related pathways may be regulated by miRNAs. We thus 167 established the regulatory network of target genes involved in key signalling pathways in the 168 endoplasmic reticulum lumen. Surprisingly, the hub miRNAs (degree > 4) in the network were 169 all consistent with the HI-DOWN miRNAs ( Figure 5C ), whose expression was found to be 170 J o u r n a l P r e -p r o o f downregulated in severe patients ( Figure 5D ). For instance, miR-335-5p may regulate 24 ER-171 related genes, including sensor genes in the three downstream pathways of the unfolded protein 172 response (UPR), including the PERK pathway, ATF6 pathway, and IRE1 pathway ( induce programmed cell death. 31 Our research indicates that small RNAs are involved in these 187 severe stress and response processes. Although we are using whole blood samples, which 188 contains multiple cell types, we believe sncRNA-induced stress response is a common pathway 189 in cells and the affection of these stress-related small RNAs should be shared by most tyeps of 190 cells. Future research can sort cells on this basis and then study the changes in these small RNAs 191 separately to verify our conclusion. In the future, in-depth verification of the expression and 192 function of these small RNAs is needed to clarify the role and mechanisms of small RNAs in 193 the occurrence and development of J o u r n a l P r e -p r o o f The most recent studies have shown that miRNAs can be used as indicator molecules for 195 detecting infections by a variety of pathogens, 32 including Hendra virus infection, 33 HIV 196 infection, 34 tuberculosis, 35 malaria, 36 and Ebola. 37 Our study revealed that the expression profile 197 of miRNAs can accurately distinguish different groups of COVID-19 patients. This finding was 198 consistent with another study showing that miRNAs can predict the prognosis of mild/cases 199 and can also identify asymptomatic infections in HBsAg carriers and chronic hepatitis B 200 patients. 38 201 As the most important type of small non-coding RNAs in cells, miRNAs are estimated to 202 regulate 60% of all protein-coding genes at the post-transcriptional level 39 can directly interact with the viral genome to inhibit its translation, 42 and miR-29 is an antiviral 208 factor induced by IL-21 in CD4 T cells. 43 In addition, the expression level of serum miR-29 is 209 negatively correlated with liver fibrotic stages and necroinflammation grades in patients with 210 chronic HBV infection. 44 Studies have confirmed that miR-335 directly regulates the stress 211 response. 45, 46 212 The UPR is induced by ER stress caused by the accumulation of misfolded protein, which is 213 highly activated after virus infection 47 . Based on the results that miRNAs are enriched in the 214 ER stress pathway, it can be speculated that after SARS-CoV-2 infection, cells may 215 downregulate the expression of a series of miRNAs to activate the downstream pathway of the 216 UPR. Previous studies have revealed that the p38 MAPK pathway is involved in viral 217 replication 48 and that the downregulation of miR-29 expression is involved in the activation of 218 caspases (CASP) and affects cell apoptosis. 49 In addition, the TGF-β signalling pathway, 219 J o u r n a l P r e -p r o o f affected by miRNAs, can also induce apoptosis. 50 The activation of these pathways further 220 amplifies the stress response of cells. As all differentially expressed genes are involved in a 221 series of downstream signalling pathways of stress, we believe that miRNA-target genes should 222 control the specificity, timing, and severity of the cell response to SARS-CoV-2 infection 223 stresses. Considering the extensive and cascade amplification effect of miRNAs on target 224 regulation, the use of miRNAs for the treatment and monitoring of infectious diseases can be 225 considered, which may also open a different way of COVID-19 treatment. 226

Our research revealed that small RNAs from the blood of COVID-19 patients are mainly 227 produced by the human genome, not by the SARS-CoV-2 genome. Growing evidence has 228

shown that a variety of viruses can produce small viral RNAs (svRNAs), including influenza, 51 229 EV71, 52 hepatitis A virus (HAV), 53 West Nile virus, 54 and SARS-CoV. 55 These svRNAs can use 230 the host's RNAi mechanism to control the mRNAs in cells, which in turn affects the fate of both 231 viruses and host cells. In addition, some studies have speculated on potential svRNAs derived 232 from the SARS-CoV-2 genome by analysis of the virus genome sequence. [56] [57] [58] In our 233 transcriptome data, we could barely detect small RNAs from SARS-CoV-2, which may be 234 caused by two hypothetical possibilities. First, SARS-CoV-2 cannot produce small RNAs after 235 entering host cells. Second, SARS-CoV-2 can produce svRNAs only in the lungs or other 236 invading tissues but cannot release them into the blood, or its production and release are affected 237 by other factors. In the future, it will be necessary to detect the presence of SARS-CoV-2 small 238 RNA in cell lines or lung tissues to verify the above hypothesis. 239

We conducted a "power analysis" to investigate whether the existing number of duplicate 240 samples in our study can support our conclusion. The results of this type of analysis have been 241 widely recognized 59, 60 . We first downloaded the data of Zheng et al. 61 on miRNA analysis of 242 COVID-19 patients during recovery, which contains PBMC data from 6 mild, 7 moderate and 243 5 severe patient blood samples. We performed the power analysis of the three group sets 244 J o u r n a l P r e -p r o o f separately (moderate vs. mild, severe vs. mild and severe vs. moderate) using the ssize.fdr R 245 package. The results showed that along with the increase in sample size, the power value also 246 gradually increased ( Figure S4A ). When the sample size was greater than 5, the power value 247 basically reached 1. When the sample size was 4, the power value of each group ranged from 248 0.81 to 0.92. In general, when the power value is greater than 0.8, the conclusion is considered 249 plausible 62 were performed by the quantifier.pl script. We allowed 3 mismatches when mapping reads to 305 precursors. Counts of reads mapping to each miRBase mature miRNA were obtained from the 306 miRDeep2 output and normalized by its default method. 307 tsRNA identification and quantification 308 tsRNA expression profiles were constructed using the tRFinder tool, which we established 309 previously. 26, 68 Briefly, the clean data were mapped to the human genome (assembly GRCh38), 310 and the unmatched data were mapped to tRNA precursors. According to the length and location 311 of these tRFs, we classified them as tRF-5, tRF-3, tRF-1, or tRF-i. 25 The read counts were 312 normalized into RPM values. The RPM is evaluated using formula (1): 313

where R represents the number of reads mapped to a particular small RNA, and N represents 315 the total number of all mapped reads form given library. All the log-transformed RPM were 316 performed using log2-transformed RPM plus 1. 317

Differentially expressed RNAs were determined using the Limma 69 package in R. The value of 319 the expression matrix was RPM, and the matrix was transformed to log2-expression values. We 320 selected 32 differentially expressed miRNAs (p value < 0.05). These miRNAs were split into 3 321 classes (Class 1 (moderate high pattern), Class 2 (healthy high pattern) and Class 3 (severe high 322 pattern)) using the ComplexHeatmap 70 Analysis of small RNA sequencing data revealed that tsRNA and microRNA levels in the blood of COVID-19 patients have undergone drastic changes, and these changes are related to stress responses. It implies that small RNA has the potential to be a drug or therapeutic target for COVID-19.

Clinical management of COVID-19: interim guidance

The trinity of COVID-19: immunity, inflammation and intervention

Pathophysiological mechanisms of disease severity in COVID-19: an update.(Special Issue: COVID-19: conventional therapies, fates, and mechanisms.)

Severe Acute Respiratory Syndrome-Associated Coronavirus 2 Infection and Organ Dysfunction in the ICU: Opportunities for Translational Research

Do inflammasome impact COVID-19 severity? Virusdisease

Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19

The emerging role of microRNAs in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection

On the Importance of Host MicroRNAs During Viral Infection

Inhibition of miR-146a prevents enterovirus-induced death by restoring the production of type I interferon

Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122

The Clinical Application of MicroRNAs in Infectious Disease

COVID-19 Virulence in Aged Patients Might Be Impacted by the Host Cellular MicroRNAs Abundance/Profile

tRNA-Derived Small RNA: A Novel Regulatory Small Non-Coding RNA

Stress-induced tRNA-derived RNAs: a novel class of small RNAs in the primitive eukaryote Giardia lamblia

Both endo-siRNAs and tRNA-derived small RNAs are involved in the differentiation of primitive eukaryote Giardia lamblia

Respiratory Syncytial Virus Utilizes a tRNA Fragment to Suppress Antiviral Responses Through a Novel Targeting Mechanism

Identification and functional characterization of tRNA-derived RNA fragments (tRFs) in respiratory syncytial virus infection

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

LTR-Retrotransposon Control by tRNA-Derived Small RNAs

Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase

tRNA-Derived Small RNAs and Their Potential Roles in Cardiac Hypertrophy

Computational Approaches to tRNA-Derived Small RNAs

tRF2Cancer: A web server to detect tRNA-derived small RNA fragments (tRFs) and their expression in multiple cancers

Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?

Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19

MicroRNA functions in stress responses

MicroRNA Biomarkers for Infectious Diseases: From Basic Research to Biosensing

Promotion of Hendra virus replication by microRNA 146a

Development and validation of plasma miRNA biomarker signature panel for the detection of early HIV-1 infection

Screening and identification of six serum microRNAs as novel potential combination biomarkers for pulmonary tuberculosis diagnosis

Identification of potential whole blood MicroRNA biomarkers for the blood stage of adult imported falciparum malaria through integrated mRNA and miRNA expression profiling

Circulating microRNA profiles of Ebola virus infection

Expression Profiling of Cellular MicroRNA in Asymptomatic HBsAg Carriers and Chronic Hepatitis B Patients

Most mammalian mRNAs are conserved targets of microRNAs

MicroRNA 181 suppresses porcine reproductive and respiratory syndrome virus (PRRSV) infection by targeting PRRSV receptor CD163

Cellular microRNA networks regulate host dependency of hepatitis C virus infection

Pediatric Obsessive-Compulsive Disorder: A Guide to Assessment and Treatment

IL-21 induces antiviral microRNA-29 in CD4 T cells to limit HIV-1 infection

Serum microRNA-29 levels correlate with disease progression in patients with chronic hepatitis B virus infection

miR-335 promotes stress granule formation to inhibit apoptosis by targeting ROCK2 in acute ischemic stroke

miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-dependent stress response

Coronavirus-induced ER stress response and its involvement in regulation of coronavirus-host interactions

Microarray analysis of microRNA expression in peripheral blood mononuclear cells of critically ill patients with influenza A (H1N1)

Dysregulated genes and miRNAs in the apoptosis pathway in colorectal cancer patients

MicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancer

Influenza A virus-generated small RNAs regulate the switch from transcription to replication

A cytoplasmic RNA virus generates functional viral small RNAs and regulates viral IRES activity in mammalian cells

Novel microRNA-like viral small regulatory RNAs arising during human hepatitis A virus infection

Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems

SARS-CoV-Encoded Small RNAs Contribute to Infection-Associated Lung Pathology

The Prediction of miRNAs in SARS-CoV-2 Genomes: hsa-miR Databases Identify 7 Key miRs Linked to Host Responses and Virus Pathogenicity-Related KEGG Pathways Significant for Comorbidities

Epigenetic Regulator miRNA Pattern Differences Among SARS-CoV, SARS-CoV-2, and SARS-CoV

World-Wide Isolates Delineated the Mystery Behind the Epic Pathogenicity and Distinct Clinical Characteristics of Pandemic COVID-19

Computational analysis of microRNAmediated interactions in SARS-CoV-2 infection

Improving power to detect changes in blood miRNA expression by accounting for sources of variability in experimental designs

Small sample sizes in high-throughput miRNA screens: A common pitfall for the identification of miRNA biomarkers

Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19

A power primer

fastp: an ultra-fast all-in-one FASTQ preprocessor

Fast gapped-read alignment with Bowtie 2

The Sequence Alignment/Map format and SAMtools

miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades

miRBase: annotating high confidence microRNAs using deep sequencing data

A web server to detect tRNA-derived small RNA fragments (tRFs) and their expression in multiple cancers

limma powers differential expression analyses for RNA-sequencing and microarray studies

Complex heatmaps reveal patterns and correlations in multidimensional genomic data

miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions

clusterProfiler: an R package for comparing biological themes among gene clusters

Cytoscape: a software environment for integrated models of biomolecular interaction networks

Sample size estimation while controlling false discovery rate for microarray experiments using the ssize. fdr package

effectsize: Estimation of effect size indices and standardized parameters

qvalue: Q-value estimation for false discovery rate control